癌症中NTRK融合的综述。
A review of NTRK fusions in cancer.
作者信息
Manea Cristina Alexandra, Badiu Dumitru Cristinel, Ploscaru Ioan Cristian, Zgura Anca, Bacinschi Xenia, Smarandache Catalin Gabriel, Serban Dragos, Popescu Cristian Gabriel, Grigorean Valentin Titus, Botnarciuc Vladimir
机构信息
Military Emergency Hospital Constanta, Ovidius University of Medicine and Pharmacy, Constanta, Romania.
General Surgery Department, Bagdasar Arseni Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
出版信息
Ann Med Surg (Lond). 2022 Jun 13;79:103893. doi: 10.1016/j.amsu.2022.103893. eCollection 2022 Jul.
The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes , and . Alterations of genes can induce carcinogenesis both in neurogenic and non-neurogenic cells. The prevalence of gene fusion is under 1% in solid tumors, but is highly encountered in rare tumors. The presence of gene fusion is associated, in some types of neoplasia, with a favorable evolution, but the presence of NTRK 2 may be associated with a poor prognosis. The identification of cancer patients harboring gene fusions is constantly growing, especially with the advent of NTRK inhibitors. This has promisingly provided a rationale for personalized therapeutics that improved outcomes in settings with this signature.
神经营养性原肌球蛋白激酶受体（NTRK或TRK）家族是负责神经元发育的跨膜酪氨酸激酶的一部分。该受体家族的成员是TRKA、TRKB和TRKC，它们分别由基因 、 和 编码。这些基因的改变可在神经源性和非神经源性细胞中诱导致癌作用。NTRK基因融合在实体瘤中的发生率低于1%，但在罕见肿瘤中很常见。在某些类型的肿瘤形成中，NTRK基因融合的存在与良好的病程相关，但NTRK 2的存在可能与预后不良有关。携带NTRK基因融合的癌症患者的识别率在不断提高，尤其是随着NTRK抑制剂的出现。这有望为个性化治疗提供理论依据，从而改善具有这种特征的患者的治疗效果。
Zotero 插件